Intellectual Property

We actively pursue and maintain intellectual property protection for our technology. We therefore seek to maintain our current and obtain additional international patent coverage for innovations that our research brings to the field of RNAi.

Our patents and patent applications include claims directed to innovative molecules and constructs, pharmaceutical formulations and therapeutic methods of use.  Our trade marks reflect the reputation that Silence has built up in the field of RNAi.

Our technology spans the following areas, all of which we seek international patent protection in:

 Specific siRNA molecules

We effectively screen for and identify potent siRNA molecules against selected targets. These potent siRNA molecules are the result of Silence’s years of know-how and proprietary design rules. 

 Stabilisation technology

Enhancing the stability of siRNA molecules is key to ensuring that they reach target cells intact and able to effectively carry out their function. Our research identified certain chemical modifications and motifs (AtuRNAiTM) that increase the stability of siRNA molecules, while making them less immunogenic.

Our patents for these modifications reflect the importance of Silence’s inventions in this area of RNAi technology. We continue to explore novel uses of chemical modifications for our potent siRNA molecules.

Our AtuRNAiTM trade mark is also recognised in the industry as being associated with Silence and its innovative contribution to the siRNA field.

 Exclusive structural features

We design innovative siRNA constructs aimed to provide enhanced potency, enhanced stability and ease of manufacture. 

Silence’s specific siRNA molecules exhibit unique structural features which, irrespective of their individual nucleotide sequence, bar third parties from commercialising this type of molecule. Such unique structural features include, for example, the use of blunt end molecules which are the subject of our patents and patent applications.

 Delivery systems

Effective delivery of siRNA to target cells has been a major challenge in the field. We have designed chemical linker systems for use with selected ligands that enable the targeting of specific cell types. Our linker structures facilitate delivery of our therapeutic siRNA molecules to target cells. 

We also have proprietary rights to various lipid components which are the core of several delivery systems we have developed. Both the core lipids and derived delivery systems are subject to various patent families.